专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016106406A2 RNA AGENTS FOR GST-PI GENE MODULATION 审中-公开
标题翻译：用于GST-PI基因调控的RNA代理
公开(公告)号：WO2016106406A2
公开(公告)日：2016-06-30
申请号：PCT/US2015/067561
申请日：2015-12-28
申请人： NITTO DENKO CORPORATION , YING, Wenbin
发明人： YING, Wenbin , MINOMI, Kenjirou , HARBORTH, Jens , TAKAHASHI, Hirokazu , TERADA, Erika , ZHANG, Jun , AHMADIAN, Mohammad
CPC分类号： C07F9/6533 , A61K31/713 , C12N15/113 , C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/322 , C12N2310/344 , C12N2310/3515 , C12N2310/531 , C12N2320/30 , C12N2320/32 , C12N2320/35 , C12N2320/53 , C12Q1/02 , G01N33/582 , C12N2310/3533 , C12N2310/3531 , C12N2310/321 , C12N2310/3521
摘要： This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding GST-π; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length
摘要翻译：本发明提供了使用RNA干扰调节人GST-π表达的化合物，组合物和方法。 RNA干扰分子可用于预防或治疗恶性肿瘤等疾病的方法。核酸分子可具有a）多核苷酸有义链和多核苷酸反义链; b）分子的每条链长度为15至30个核苷酸; c）反义链的15至30个核苷酸的连续区域与编码GST-π的mRNA的序列互补; 和d）有义链的至少一部分可以与反义链的至少一部分互补，并且该分子具有长度为15至30个核苷酸的双链体区

2. 发明申请

WO2016060135A1 モルフォリノオリゴヌクレオチドの製造方法审中-公开
标题翻译：莫比诺寡糖制备方法
公开(公告)号：WO2016060135A1
公开(公告)日：2016-04-21
申请号：PCT/JP2015/078960
申请日：2015-10-13
申请人：味の素株式会社
发明人：高橋　大輔 , 鳥居　高好
IPC分类号： C07F9/6533 , C07F9/6558 , C12N15/09 , A61K31/7052
CPC分类号： C12N15/111 , A61K31/7052 , C07F9/6533 , C07F9/6558 , C12N15/09 , C12N15/113 , C12N2310/11 , C12N2310/3233 , Y02P20/55
摘要：　本発明は、縮合反応の反応混合物を抽出操作に付し、有機層側に生成物であるモルフォリノオリゴヌクレオチドを分離することを特徴とするモルフォリノオリゴヌクレオチドの液相合成法に関し、本発明によれば、液相合成法において効率的かつ高収率にモルフォリノオリゴヌクレオチドを製造できる方法を提供することができる。
摘要翻译：本发明涉及一种吗啉代寡核苷酸液相合成方法，其特征在于使缩合反应的反应混合物进行提取操作，并在有机层中分离产物吗啉代寡核苷酸。本发明提供能够在液相合成法中有效且高收率地制备吗啉代寡核苷酸的方法。

3. 发明申请

WO2015035231A1 ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE 审中-公开
标题翻译：抗酸诱导的EXON2包含在酸性阿尔法 - 葡萄糖苷酶中
公开(公告)号：WO2015035231A1
公开(公告)日：2015-03-12
申请号：PCT/US2014/054384
申请日：2014-09-05
申请人： SAREPTA THERAPEUTICS, INC. , MURDOCH UNIVERSITY
发明人： WILTON, Stephen Donald , FLETCHER, Sue , HANSON, Gunnar James , BESTWICK, Richard Keith
IPC分类号： C12N15/113 , A61K31/712 , A61K31/7125 , C07H21/00
CPC分类号： C12N15/1137 , C07F9/6533 , C12N2310/11 , C12N2310/3145 , C12N2310/315 , C12N2310/3181 , C12N2310/321 , C12N2310/3231 , C12N2310/3233 , C12N2310/3513 , C12N2320/33 , C12Y302/0102
摘要： The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.
摘要翻译：本公开内容涉及用于诱导外显子包含的反义寡聚体和相关组合物和方法，作为II型糖原贮积病（GSD-II）（也称为庞培病，糖原II，酸性麦芽糖酶缺乏（AMD），酸性α- 葡萄糖苷酶缺乏和溶酶体α-葡糖苷酶缺乏），更具体地涉及诱导外显子2的包含，从而恢复由GAA基因编码的酶活性的酸性α-葡萄糖苷酶（GAA）蛋白的水平。

4. 发明申请

WO2012082568A1 PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS 审中-公开
标题翻译：作为化学受体调节剂的磷酸衍生物
公开(公告)号：WO2012082568A1
公开(公告)日：2012-06-21
申请号：PCT/US2011/064242
申请日：2011-12-09
申请人： ALLERGAN, INC. , YUAN, Haiqing , BEARD, Richard, L. , LIU, Xiaoxia , DONELLO, John, E. , VISWANATH, Veena , GARST, Michael, E.
发明人： YUAN, Haiqing , BEARD, Richard, L. , LIU, Xiaoxia , DONELLO, John, E. , VISWANATH, Veena , GARST, Michael, E.
IPC分类号： C07F9/32 , A61K31/662 , C07F9/36
CPC分类号： C07C311/21 , C07C317/34 , C07C317/36 , C07C317/42 , C07C317/44 , C07C317/50 , C07C321/30 , C07C323/49 , C07C323/52 , C07C323/56 , C07C323/60 , C07C323/67 , C07C2601/08 , C07D207/09 , C07D207/46 , C07D213/32 , C07D213/52 , C07D233/64 , C07D277/40 , C07D295/13 , C07D295/185 , C07D295/24 , C07D307/64 , C07D307/82 , C07D333/34 , C07D405/12 , C07D413/12 , C07D417/12 , C07F9/304 , C07F9/3229 , C07F9/4021 , C07F9/5325 , C07F9/591 , C07F9/6533
摘要： The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
摘要翻译：本发明涉及新型磷衍生物，其制备方法，含有它们的药物组合物及其作为药物作为趋化因子受体调节剂的用途。

5. 发明申请

WO2012068335A2 NOVEL CATALYSTS 审中-公开
标题翻译：新型催化剂
公开(公告)号：WO2012068335A2
公开(公告)日：2012-05-24
申请号：PCT/US2011061130
申请日：2011-11-17
申请人： UNIV DALHOUSIE , LUNDGREN RYLAN J , STRADIOTTO MARK
发明人： LUNDGREN RYLAN J , STRADIOTTO MARK
IPC分类号： C07F9/6527
CPC分类号： B01J31/2452 , B01J31/189 , B01J31/2404 , B01J31/2409 , B01J31/2414 , B01J31/2433 , B01J2231/32 , B01J2231/4283 , B01J2531/18 , B01J2531/824 , C07C209/06 , C07C209/60 , C07C213/02 , C07C221/00 , C07C227/08 , C07C241/02 , C07C249/02 , C07C319/20 , C07C2601/14 , C07D231/56 , C07F9/5018 , C07F9/5022 , C07F9/5532 , C07F9/5683 , C07F9/591 , C07F9/598 , C07F9/645 , C07F9/650958 , C07F9/6524 , C07F9/6533 , C07F9/6536 , C07F9/6544 , C07F9/65583 , C07F15/006 , C07C211/28 , C07C211/40 , C07C243/22 , C07C249/16 , C07C251/86 , C07C323/48 , C07C211/47 , C07C211/45 , C07C211/46 , C07C211/54 , C07C217/86 , C07C323/36 , C07C217/84 , C07C211/49 , C07C211/50 , C07C211/51 , C07C211/52 , C07C211/58 , C07C215/68 , C07C215/76 , C07C225/22 , C07C251/24 , C07C229/60
摘要： The present invention provides novel compounds and ligands that are useful in transition metal catalyzed cross-coupling reactions. For example, the compounds and ligands of the present invention are useful in palladium or gold catalyzed cross-coupling reactions.
摘要翻译：本发明提供了可用于过渡金属催化的交叉偶联反应的新型化合物和配体。例如，本发明的化合物和配体可用于钯或金催化的交叉偶联反应。

6. 发明申请

WO2011023795A1 (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS 审中-公开
标题翻译：（THIO）吗啉衍生物作为S1P调节剂
公开(公告)号：WO2011023795A1
公开(公告)日：2011-03-03
申请号：PCT/EP2010/062552
申请日：2010-08-27
申请人： ABBOTT HEALTHCARE PRODUCTS B.V. , IWEMA BAKKER, Wouter, I. , COOLEN, Hein K.A.C. , MONS, Harmen , STOIT, Axel , RONKEN, Eric , KAM, VAN DER, Elizabeth , FRANKENA, Jurjen
发明人： IWEMA BAKKER, Wouter, I. , COOLEN, Hein K.A.C. , MONS, Harmen , STOIT, Axel , RONKEN, Eric , KAM, VAN DER, Elizabeth , FRANKENA, Jurjen
IPC分类号： C07D265/30 , C07D265/32 , C07D413/12 , C07D419/12 , C07D471/04 , A61K31/5377 , A61P25/04 , A61P25/06 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , C07D279/12 , C07D417/12 , C07D487/04
CPC分类号： C07D295/15 , C07D265/30 , C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D413/12 , C07D417/12 , C07D471/04 , C07F9/6533
摘要： The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO 2 -(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH 3 -O- and the linking group –Y-(CH 2 ) n -X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO 2 -, -CH 2 -O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO 2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH 2 ) 2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH 2 -R5, wherein R5 is -OH, -PO 3 H 2 , -OPO 3 H 2 , -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO 2 -; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.
摘要翻译：本发明涉及式（I）的（硫代）吗啉衍生物，其中R 1选自氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烷基，（6-8C）双环烷基，（8-10C）双环基团，各自任选被（1-4C）烷基，苯基，联苯基，萘基取代，各自任选被一个或多个独立地选自卤素，（1- 氨基，二（1-4C）烷基氨基，-SO 2 - （1-4C）烷氧基，被一个或多个氟原子烷基取代的（2-4C）炔基，任选被一个或多个氟原子取代的（1-4C）） - （1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，被苯氧基取代的苯基（1-4C）烷基或任选被（1-4C）烷基任意取代的苯基的单环杂环，和任选被取代的（1-4C）烷基的双环杂环，与（1-4C）烷基; A选自-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C = C-，-CCH 3 -O-和连接基-Y-（CH 2）n X- 其中Y连接到R 1并且选自-O - ， - S - ， - SO - ， - SO 2 - ， - CH 2 -O-，-CO-，-O-CO-，-CO-O-， -CO-NH-，-NH-CO-，-C≡C-和-C = C-; n为1〜10的整数，并且X连接到亚苯基/吡啶基上，并且选自-O - ， - S - ， - SO - ， - SO 2 - ， - NH，-CO - ， - C = C - 和-C = C- ; 环结构B任选地含有一个氮原子; R2是H，任选被一个或多个氟原子取代的（1-4C）烷基，（1-4C）任选被一个或多个氟原子取代的烷氧基或卤素; 并且R 3是（1-4C）亚烷基-R 5，其中亚烷基可以被（CH 2）2取代以形成环丙基部分或一个或两个卤素原子，或者R 3是（3-6C）亚环烷基-R 5或-CO -CH 2 -R 5，其中R 5是-OH，-PO 3 H 2，-OPO 3 H 2，-COOH，-COO（1-4C）烷基或四唑-5-基; R4是H或（1-4C）烷基; R6是一个或多个独立地选自H，（1-4C）烷基或氧代的取代基; W是-O - ， - S - ， - SO-或-SO 2 - ; 或其药学上可接受的盐，溶剂合物或水合物; 条件是式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉代乙醇或4- [4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂合物或水合物。本发明的化合物对S1P受体具有亲和力，可用于治疗，缓解或预防S1P受体介导的疾病和病症。

7. 发明申请

WO2004041167A2 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS 审中-公开
标题翻译：抗原体环取代的磷脂
公开(公告)号：WO2004041167A2
公开(公告)日：2004-05-21
申请号：PCT/US2003/034225
申请日：2003-10-29
申请人： CALOGEROPOULOU, Theodora , KOUFAKI, Maria , AVLONITIS, Nikolaos , MAKRIYANNIS, Alexandros
发明人： CALOGEROPOULOU, Theodora , KOUFAKI, Maria , AVLONITIS, Nikolaos , MAKRIYANNIS, Alexandros
IPC分类号： A61K
CPC分类号： C07F9/6533 , C07F9/091 , C07F9/117 , C07F9/591
摘要： Disclosed are novel ring containing phospholipids represented by the structural formula A-X-PO 3 -W and physiologically acceptable salts thereof and a process for the preparation of these compounds. The compounds can be used for the treatment of protozoal diseases and especially leishmaniasis.
摘要翻译：公开了由结构式A-X-PO 3 -W所代表的含有磷脂的新型环及其生理学上可接受的盐以及制备这些化合物的方法。这些化合物可用于治疗原虫疾病，特别是利什曼病。

8. 发明申请

WO0220500A3 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT 审中-公开
标题翻译：阻止癌症治疗的材料和方法
公开(公告)号：WO0220500A3
公开(公告)日：2003-07-31
申请号：PCT/US0126709
申请日：2001-08-28
申请人： ICOS CORP
发明人： HALBROOK JAMES , KESICKI EDWARD , BURGESS LAURENCE E , SCHLACHTER STEPHEN T , EARY CHARLES T , SCHIRO JUSTIN G , HUANG HONGMEI , EVANS MICHAEL , HAN YONGXIN
IPC分类号： A61K45/06 , A61P35/00 , C07C309/66 , C07D209/36 , C07D211/42 , C07D211/46 , C07D213/40 , C07D213/50 , C07D213/74 , C07D213/75 , C07D233/54 , C07D235/26 , C07D239/48 , C07D277/24 , C07D277/42 , C07D277/46 , C07D277/54 , C07D279/12 , C07D295/096 , C07D295/112 , C07D295/13 , C07D295/135 , C07D295/155 , C07D295/185 , C07D295/215 , C07D295/30 , C07D307/83 , C07D309/10 , C07D311/30 , C07D333/22 , C07D405/04 , C07D417/12 , C07D521/00 , C07F9/6533 , C07F9/6578 , C07D295/12 , A61K31/435 , C07C309/44 , C07D211/26 , C07D239/42 , C07D295/08 , C07D295/10 , C07D295/14 , C07D295/18 , C07D295/20 , C07D295/22 , C07D417/04 , C07F11/00 , G01N33/53
CPC分类号： C07D213/40 , A61K45/06 , C07C309/66 , C07D209/36 , C07D211/42 , C07D211/46 , C07D213/50 , C07D213/74 , C07D213/75 , C07D231/12 , C07D233/56 , C07D235/26 , C07D239/48 , C07D249/08 , C07D277/24 , C07D277/54 , C07D279/12 , C07D295/096 , C07D295/112 , C07D295/13 , C07D295/135 , C07D295/155 , C07D295/185 , C07D295/215 , C07D295/30 , C07D307/83 , C07D309/10 , C07D311/30 , C07D333/22 , C07D405/04 , C07D417/12 , C07F9/6533 , C07F9/65785
摘要： Compounds of Formula (I) that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
摘要翻译：公开了抑制DNA依赖性蛋白激酶的式（I）化合物，包含该化合物的组合物，抑制DNA-PK生物活性的方法，使细胞致敏引起DNA损伤的试剂的方法以及加强癌症治疗的方法。

9. 发明申请

WO99041245A1 INSECTICIDAL DIHYDRO-OXADIAZINES, -THIADIAZINES AND -TRIAZINES 审中-公开
标题翻译：杀虫剂二氢 - 氧化物，乙二胺四乙酸
公开(公告)号：WO99041245A1
公开(公告)日：1999-08-19
申请号：PCT/US1999/001245
申请日：1999-01-22
IPC分类号： A01N47/38 , A01N57/24 , C07D253/06 , C07D273/04 , C07D285/16 , C07D413/04 , C07D498/04 , C07F9/6533
CPC分类号： C07D253/06 , A01N47/38 , A01N57/24 , C07D273/04 , C07D285/16 , C07D413/04 , C07F9/6533
摘要： Insecticidal dihydro-oxadiazine compounds having formula (I): wherein X is O, N or S; R is a substituted or unsubstituted phenyl or C4-C5 heterocyclic group; R , R , R , and R are one of the following: a) R , R , and R are independently, hydrogen, alkyl, alkoxy, or furanyl; and R is nitro, cyano, alkyl, dialkylamino, alkylthio, alkoxy, haloalkoxy, phenoxy, phenylthio, or alkoxycarbonyl, wherein R and R together can form a ring; or b) R , R , and R are hydrogen; and R is alkylthio, alkylsulfinyl, alkylsulfonyl, nitroalkoxy, hydroxy, dialkoxyphosphinyl, cyano, acyloxy, alkoxy, haloalkoxy, cycloalkyl, or alkenyl; or R is a substituted or unsubstituted phenyl, phenylthio, phenylsulfinyl, phenylsulfonyl, pyrazolyl, furanyl, thienyl, phenylalkoxy, or benzoyloxy; and R is hydrogen alkyl, alkylthio, alkoxyalkyl, acyl, benzyl, or alkoxycarbonyl.
摘要翻译：具有式（I）的杀虫二氢 - 恶二嗪化合物：其中X是O，N或S; R是取代或未取代的苯基或C 4 -C 5杂环基; R 2，R 3，R 4和R 5是以下之一：a）R 2，R 3和R 4独立地是氢，烷基，烷氧基或呋喃基; R 5为硝基，氰基，烷基，二烷基氨基，烷硫基，烷氧基，卤代烷氧基，苯氧基，苯硫基或烷氧基羰基，其中R 3和R 5一起可以形成环; 或b）R 3，R 4和R 5是氢; R 2是烷硫基，烷基亚磺酰基，烷基磺酰基，硝基烷氧基，羟基，二烷氧基氧膦基，氰基，酰氧基，烷氧基，卤代烷氧基，环烷基或烯基; 或R 2是取代或未取代的苯基，苯硫基，苯基亚磺酰基，苯基磺酰基，吡唑基，呋喃基，噻吩基，苯基烷氧基或苯甲酰氧基; R 6是氢烷基，烷硫基，烷氧基烷基，酰基，苄基或烷氧基羰基。

10. 发明申请

WO1997009335A1 SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS 审中-公开
标题翻译：取代的磷化合物及其作为药物的用途
公开(公告)号：WO1997009335A1
公开(公告)日：1997-03-13
申请号：PCT/GB1996002113
申请日：1996-08-30
申请人： CIBA-GEIGY AG , FRÖSTL, Wolfgang , MICKEL, Stuart, John , COOKE, Nigel, Graham , BENNETT, Stuart, Norman, Lile , WILLIAMS, Anne, Rachel, Burton
发明人： CIBA-GEIGY AG
IPC分类号： C07F09/6533
CPC分类号： C07F9/65583 , C07C215/28 , C07C229/36 , C07C229/38 , C07C255/41 , C07C255/42 , C07C271/16 , C07C271/22 , C07F9/301 , C07F9/302 , C07F9/3211 , C07F9/3217 , C07F9/48 , C07F9/5728 , C07F9/6533 , Y02P20/55
摘要： A compound which is a substituted phosphinic acid of formula (I), or a salt or ester thereof, where R is a monovalent aromatic or araliphatic group connected through a carbon atom thereof to the indicated carbon atom, R is an unsubstituted or substituted hydrocarbyl group, R is hydrogen or an unsubstituted or substituted hydrocarbyl group, R is hydrogen, R a or a NH-protecting group and R a is an unsubstituted or substituted hydrocarbyl group.
摘要翻译：作为式（I）的取代的次膦酸的化合物或其盐或酯，其中R 1是通过其碳原子与指定的碳原子连接的一价芳族或芳脂族基，R 2是未取代或取代的烃基，R x是氢或未取代或取代的烃基，R y是氢，R a a或NH保护基，R a是未取代或取代的烃基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式